← Eichor
Study identifier: NCT06014190 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Condition: Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer  ·  Sponsor: Hansoh BioMedical R&D Company

PhasePhase 2
Planned participants460
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average drug-to-antibody ratio of about 6. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20089 as monotherapy in patients with recurrent or metastatic ovarian cancer and endometrial cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Lingying Wu, MD  ·  010-87788996  ·  wulingying@csco.org.cn

Dawei Wu  ·  010-87788495  ·  cancergcp@163.com

Always discuss trial participation with your own doctor first.

Locations (28)

Anhui Provincial Cancer HospitalHefei, Anfei, ChinaRecruiting
Lingying WuBeijing, Beijing Municipality, ChinaRecruiting
Peking University Cancer HospitalBeijing, Beijing Municipality, ChinaRecruiting
Chongqing University cancer HospitalChongqing, Chongqing Municipality, ChinaSuspended
Fujian Cancer HospitalFuzhou, Fujian, ChinaRecruiting
Sun Yat-Sen Memorial Hospital Sun Yat-Sen UniversityGuangzhou, Guangdong, ChinaRecruiting
Guangxi Cancer HospitalNanning, Guangxi, ChinaRecruiting
Hainan General HospitalHaikou, Hainan, ChinaRecruiting
The fourth Hospital of Heibei Medical UniversityShijiazhuang, Hebei, ChinaRecruiting
Harbin Medical University Cancer HospitalHarbin, Heilongjiang, ChinaRecruiting
Henan Cancer HospitalZhengzhou, Henan, ChinaRecruiting
Hubei Cancer UniversityWuhan, Hubei, ChinaRecruiting

+ 16 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06014190